Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04842747 | VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study | PHASE3 | COMPLETED | 204 | — | — | May 18, 2021 | Jul 6, 2022 | Apr 18, 2023 | 58 | United States, Argentina +4 |
Efficacy of VERU-111 in the treatment of SARS-Cov- 2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
| Arm | Type | Description |
|---|---|---|
| 9mg of VERU-111 Oral daily | EXPERIMENTAL | 9mg of VERU-111 |
| Placebo Capsule once daily | NO_INTERVENTION | Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital. |
| Name | Type | Description |
|---|---|---|
| VERU-111 | DRUG | Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital. |
Inclusion Criteria: * Provide informed consent from the subject or the subject's Legally Authorized Representative (LAR) * Aged ≥18 years * Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test * Patients with a WHO Ordinal Scale for ...